Fulgent Genetics, Inc.
FLGTNASDAQHealthcare● Active
$18.31
$-0.84(-4.39%)
Market Cap$520015407
P/E Ratio—
52W High$31.04
52W Low$13.46
Fulgent Genetics, Inc. (FLGT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FLGT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.32B | $0.28B | $0.29B | $0.62B | $0.99B |
| Cost of Revenue | $0.19B | $0.18B | $0.18B | $0.25B | $0.22B |
| Gross Profit | $0.13B | $0.11B | $0.10B | $0.37B | $0.78B |
| Gross Margin %(computed) | 40.56% | 37.82% | 36.12% | 59.28% | 78.29% |
| Operating Expenses | |||||
| R&D Expenses | $0.05B | $0.05B | $0.04B | $0.03B | $0.02B |
| G&A Expenses | $0.12B | $0.09B | $0.09B | $0.11B | $0.05B |
| Total Operating Expenses | $0.22B | $0.18B | $0.30B | $0.19B | $0.10B |
| Operating Income | ($0.09B) | ($0.07B) | ($0.20B) | $0.18B | $0.68B |
| Operating Margin %(computed) | -28.23% | -26.08% | -67.61% | 28.84% | 68.10% |
| Interest Income | $0.03B | $0.03B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.07B) | ($0.05B) | ($0.17B) | $0.18B | $0.68B |
| Income Tax Expense | ($0.01B) | ($0.01B) | $0.00B | $0.04B | $0.17B |
| Net Income | ($0.06B) | ($0.04B) | ($0.17B) | $0.14B | $0.51B |
| Net Margin %(computed) | -18.75% | -15.07% | -58.03% | 23.17% | 51.12% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.97 | $-1.41 | $-5.63 | $4.76 | $17.13 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B |
| EBITDA | ($0.05B) | ($0.05B) | ($0.15B) | $0.22B | $0.69B |
| EBITDA Margin %(computed) | -14.20% | -17.28% | -50.98% | 35.17% | 69.21% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Fulgent Genetics, Inc. data
About Fulgent Genetics, Inc. (FLGT) Income Statement
Fulgent Genetics, Inc. (FLGT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, FLGT reported revenue of $0.32B, gross profit of $0.13B (gross margin 40.56%), and net income of ($0.06B) — a net profit margin of -18.75%.
Frequently asked questions
FLGT · 4 questionsFulgent Genetics, Inc. (FLGT) reported revenue of $0.32B for 2025, up 13.8% year-over-year.
FLGT revenueFLGT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08